Irinotecan - DNA Topoisomerase Inhibitors- (May 1997)
Drug Name:
Irinotecan - DNA Topoisomerase Inhibitors- (May 1997)
List Of Brands:
Indication Type Description:
Drug Interaction:
Diuretics increases risk of dehydration secondary to vomiting/diarrhea Prophylactic dexamethasone s anantiemetic may enhance lypmphocytopenia
Prochlorperazine may increase incidence of akaathisia reduce irinotecan exposure
Indication:
Refractory colorectal malignancies
Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Irinotecan Hcl Anti cancer 23-05-1997
Trihydrate
Adverse Reaction:
Netropenia, anemia Thrombocytopenia, acute diarrhoea, Sweating, hyersalivation Abdominal cramps Lachrymation Miosis Weakness Nausea, vomiting Alopecia and skin reactions CV toxicity Fatal sepsis due to myelosuppression Severe chronic diarrhoea
Contra-Indications:
Inflammatory bowel disease Bowel obstruction Severe hepatic impairment Pregnancy Lactation
Special precautions Previuos pelvic/abdominal irradiation
Raised plasma -bilirubin concnentration Sevee myelosuppression Avoid extravasation
Dosages/ Overdosage Etc:
Refractory colorectal malignancies
Dosage-
125mg/m2 infused i.v. over 90 minutes once weekly for 4 weeks followed by a2 week rest period or, 350mg/m2 infused over 90 min repeated once every 3 week
Metastatic colorectal cancer as 1st line treatment 25mg.m2 infused iv over 90min on days 1.8.25, and 22 of a 6 week cycle alternnately, 180mg/m2 infused iv over 90min on days 1.15, and 29 of 8 week cycle
Pregnancy and lactation:
Use cotraindicated.Observe caution